Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients

J Pediatr Hematol Oncol. 2010 Jan;32(1):e31-7. doi: 10.1097/MPH.0b013e3181bf5e2d.

Abstract

This report describes a safe and effective therapy through adoptive transfer of donor cytomegalovirus (CMV)/Epstein-Barr virus (EBV) immune effector cells. The patients, from 3 to 10 years of age, suffering from hematologic diseases received haploidentical transplantation. All 3 patients developed varying levels of viremia from days 13 to 31 and 2 patients developed CMV-interstitial pneumonitis or interstitial inflammation after transplantation. Tapering down the dose of immunosuppressives together with intensive antivirus therapy and escalated infusions of donor-derived CMV/EBV immune effector cells effectively controlled virus-related diseases. All 3 patients survived and remained CMV/EBV-free 14-16 months after transplantation.

Publication types

  • Case Reports
  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer / methods*
  • Child
  • Child, Preschool
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / prevention & control
  • Dendritic Cells / transplantation
  • Dendritic Cells / virology
  • Epstein-Barr Virus Infections / etiology
  • Epstein-Barr Virus Infections / prevention & control
  • Female
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Male
  • Premedication / methods*
  • Survival Rate
  • T-Lymphocytes, Cytotoxic / transplantation
  • T-Lymphocytes, Cytotoxic / virology
  • Treatment Outcome